GCG and metabolic dysfunction-associated steatotic liver disease: A recent study on a HepG2 cell culture model of NAFLD treated with liraglutide found reduced activation of the NLRP3 inflammasome, as well as mTORC1 signaling inhibition, in response to GLP1-RA treatment [79].